Threshold analysis of Helicobacter pylori therapy

PharmacoEconomics

Volumn 14, Issue 4, 1998, Pages 423-432

  Sonnenberg, Amnon ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; DRUG COST; DYSPEPSIA; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NEW MEXICO; PEPTIC ULCER; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031669017     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814040-00008     Document Type: Article

References (20)

1. Imperiale TF, Speroff T, Cebul RD, et al. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123: 665-72
2. O'Brien B, Goeree R, Mohamed HA, et al. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64
3. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8
4. Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997; 350: 70-2
5. Axon AT. Chronic dyspepsia: who needs endoscopy? Gastroenterology 1997; 112: 1376-80
6. Ofman JJ, Etchason J, Fullerton S, et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126: 280-91
7. Patel P, Khulusi S, Mendall MA, et al. Prospective screening of dyspeptic patients by Helicobacter serology. Lancet 1995; 346: 1315-8
8. Sobala GM, Crabtreee JE, Pentith JA, et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991; 338: 94-6
9. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht consensus report. Gut 1997; 41: 8-13
10. Blaser MJ. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet 1997; 349: 1020-2
11. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9
12. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980; 302: 1109-17
13. Singelton RR, Tyndall WF. Games and programs: mathematics for modeling. San Francisco: WH Freeman and Company, 1974
14. Lind T, Veldhuyzen van Zanten S, Unger P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1: 138-44
15. Laheij RJF, Jansen JBMJ, van de Lisdonk EH, et al. Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10: 843-50
16. Veldhuyzen van Zanten SJO, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 1994; 150: 177-85
17. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996; 91: 1773-7
18. Briggs AH, Sculpher MJ, Logan RPH, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996; 312: 1321-5
19. Silverstein MD, Petterson T, Talley N. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83
20. Luce RD, Raiffa H. Games and decisions. New York: Dover, 1957